Eli Lilly: FDA approves first therapy for RET-driven tumors

(CercleFinance.com) - The Food and Drug Administration has approved a new treatment for patients with advanced RET-driven lung and thyroid cancers, the first for use in the United States.


More specifically, the FDA has approved Eli Lilly's Retevmo for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer and the treatment of adult and pediatric patients with advanced or metastatic RET-mutant medullary thyroid cancer.

It appears, in particular, that the majority of metastatic lung cancer patients experienced clinically meaningful responses when treated with the drug in a clinical trial, including responses in difficult-to-treat brain metastases.

Copyright (c) 2020 CercleFinance.com. All rights reserved.